◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › M › MEDEZE

MEDEZE_MEDEZE GROUP (MEDEZE) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Medical Care Facilities · DATA UPDATED 2026-08-22

MEDEZE_MEDEZE GROUP (MEDEZE) operates in the Medical Care Facilities industry and is headquartered in Nakhon Pathom, Thailand. Its market capitalization is roughly THB 7 billion. In the fiscal year ended 2025-12-31, MEDEZE reported THB 744M in revenue and THB 196M in net income.

Medeze Group Public Company Limited engages in collection and storage of stem cells for use in medication in Thailand, Vietnam, Cambodia, Philippines, and internationally. The company operates through four segments: Stem Cells; Natural Killer Cells; Others; and Sales of Products.

Interactive charts & full statements →

MEDEZE Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31
Total Revenue	THB 744M	THB 829M	THB 702M
Gross Profit	THB 547M	THB 648M	THB 550M
Operating Income (EBIT)	THB 228M	THB 364M	THB 304M
Net Income	THB 196M	THB 339M	THB 240M

THB; THBM / THBB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MEDEZE Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	THB 163M	THB 175M	THB 170M	THB 193M	THB 205M
Gross Profit	THB 123M	THB 122M	THB 120M	THB 145M	THB 160M
Operating Income (EBIT)	THB 53M	THB 39M	THB 41M	THB 61M	THB 83M
Net Income	THB 34M	THB 36M	THB 30M	THB 55M	THB 75M

THB; THBM / THBB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MEDEZE Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31
Dividends Paid	(THB 171M)	(THB 333M)	(THB 270M)

THB; THBM / THBB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MEDEZE Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Dividends Paid	THB 0M	(THB 85M)	THB 0M	(THB 85M)	THB 0M	—

THB; THBM / THBB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MEDEZE Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31
Total Assets	THB 3.5B	THB 3.4B	THB 1.0B
Total Liabilities	THB 565M	THB 506M	THB 444M

THB; THBM / THBB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MEDEZE viewer.

Other Companies in Medical Care Facilities

SKR · Sikarin Public Company Limited — THB 16 billion
PR9 · Praram 9 Hospital Public Company Limited — THB 15 billion
FME · Fresenius Medical Care AG — €11 billion
8769 · Advantage Risk Management Co., Ltd. — JPY 8 billion
6059 · UCHIYAMA HOLDINGS Co.,Ltd. — JPY 7 billion
PRINC · Principal Capital Public Company Limited — THB 7 billion
2273 · Gushengtang Holdings Limited — HK$6 billion
VIH · Srivichaivejvivat Public Company Limited — THB 6 billion

← MEDCL All “M” companies MEDI →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.